Solid Biosciences
Solid Biosciences Inc is an American clinical-stage life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The company advances its proprietary AAV gene therapy candidates including SGT-003 for Duchenne muscular dystrophy alongside gene therapy programs for catecholaminergic polymorphic ventricular tachycardia (CPVT) and Friedreich's ataxia. Revenue is currently driven through development milestone payments, strategic partnerships, and capital raises prior to commercial authorization. Core end markets serve pediatric neurology clinics, rare disease institutes, cardiology research centers, and clinical prescription patients globally. Solid Biosciences holds an innovative position in the biopharmaceutical sector as a specialized developer of next-generation capsid-engineered AAV gene therapies. The company is headquartered in Charlestown, Massachusetts, and its common stock trades on the Nasdaq Global Select Market.
2 of the funds FundTelligence covers report a position in Solid Biosciences.
- Legal name
- Solid Biosciences Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
- Exposure themes
- Gene Therapy, Genetic Medicine, Precision Medicine & Genomics
Funds holding Solid Biosciences
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.95 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.05 % (full portfolio disclosed, October 2026)